Aquestive Therapeutics, Inc. Increase (Decrease) in Finance Receivables
Aquestive Therapeutics, Inc. (AQST) reported Increase (Decrease) in Finance Receivables of -$675.00 thousand for the 9-month period ending 2022-09-30, per its 10-Q filed 2022-11-01.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInFinanceReceivables · last filed 2022-11-01
- 2022-09-30: Increase (Decrease) in Finance Receivables 9 month -$675.00K.
- 2021-09-30: Increase (Decrease) in Finance Receivables 9 month $0.00.
| Period end | Increase (Decrease) in Finance Receivables 9 month |
|---|---|
| 2022-09-30 | -$675.00K 10-Q · filed 2022-11-01 |
| 2021-09-30 | $0.00 10-Q · filed 2022-11-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |